Статья
АНТИТРОМБОТИЧЕСКАЯ ТЕРАПИЯ ПРИ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ: НОВЫЕ ДАННЫЕ И НОВЫЕ ГОРИЗОНТЫ
Освещены новые данные и перспективы антитромботической терапии у пациентов с фибрилляцией предсердий. Рассмотрены факторы эффективности терапии варфарином, а также возможности применения новых антитромботических препаратов. Особое внимание уделено прямому ингибитору тромбина — дабигатрану. Детально обсуждены возможности и перспективы его применения у пациентов с фибрилляцией предсердий в свете представленных результатов исследования RE-LY.
1. Hart R.G., Pearce, L.A., Rothbart, R.M. et al. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. JACC 2000; 35(1): 183-187.
2. Hart R.G., Pearce, L.A., Koudstaal, P.J. Transient Ischemic Attacks in Patients With Atrial Fibrillation: Implications for Secondary Prevention: The European Atrial Fibrillation Trial and Stroke Prevention in Atrial Fibrillation III Trial. Stroke 2004; 35(4): 948 - 951.
3. Hohnloser S.H., Pajitnev D., Pogue, J. at al. Incidence of Stroke in Paroxysmal Versus Sustained Atrial Fibrillation in Patients Taking Oral Anticoagulation or Combined Antiplatelet Therapy: An ACTIVE W Sub-study. JACC 2007; 50(22): 2156 - 2161.
4. Kannel W.B., Abbott, R.D., Savage D.D., McNamara P.M. Coronary heart disease and atrial fibrillation: the Framingham Study. Am Heart J 1983; 106(2): 389 - 396.
5. Nieuwlaat R., Dinh, T., Olsson S.B. et al. Should we abandon the common practice of withholding oral anticoagulation in paroxysmal atrial fibrillation? Eur Heart J 2008; 29(7): 915 - 922.
6. Hart R.G., Pearce, L.A., Aguilar M.I. Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation. Ann Intern Med 2007; 146(12): 857 - 867.
7. The ACTIVE Writing Group. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367(9526): 1903 - 1912.
8. Giliarov M.Iu., Generozov É.V., Magomadova M.U. et al. Factors influencing on warfarin dose in patients with atrial fibrillation. Kardiologiya i serdechno-sosudistaya khirurgiya 2008; 5: 65 - 68. Russian (Гиляров М.Ю., Генерозов Э.В., Магомадова М.У. и др. Факторы, влияющие на дозировку варфарина у пациентов с фибрилляцией предсердий. Кардиология и сердечно-сосудистая хирургия 2008; 5: 65 – 68).
9. Giliarov M.Iu., Generozov É.V., Magomadova M.U. et al. Polymorphism of vitamin K epoxide-reductase subunit 1 gene: prevalence and impact on warfarin dosage among Moscow region inhabitants. Kardiologiya i serdechno-sosudistaya khirurgiya 2009; 3: 36 - 39. Russian (Гиляров М.Ю., Генерозов Э.В., Магомадова М.У. и др. Полиморфизм гена субъединицы 1 витамин К эпоксидредуктазы: распространенность и влияние на дозировку варфарина у жителей Московского региона. Кардиология и сердечно-сосудистая хирургия 2009; 3: 36 – 39).
10. The ACTIVE Investigators. Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation. N Engl J Med 2009; 360(20): 2066 - 2078.
11. Cleland J.G.F., Cowburn P.J., Falk R.H. Should all patients with atrial fibrillation receive warfarin? Evidence from randomized clinical trials. Eur Heart J 1996; 17(5): 674 - 681.
12. Hylek E.M., Skates S.J., Sheehan M.A., Singer D.E. An Analysis of the Lowest Effective Intensity of Prophylactic Anticoagulation for Patients with Nonrheumatic Atrial Fibrillation. N Engl J Med 1996; 335(8): 540 - 546.
13. Gilyarov M.Yu., Sulimov V.A. Antithrombotic therapy at an atrial fibrillation: old problems and new solutions. Rational Pharmacother Cardiol 2010;6(1):84-88. Russian (Гиляров М.Ю., Сулимов В.А. Антитромботическая терапия при фибрилляции предсердий: старые проблемы и новые решения. Рациональная Фармакотерапия в Кардиологии 2010; 6(1): 84-88).
14. Connolly S.J., Ezekowitz M.D., Yusuf S. et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2009; 361(12): 1139 - 1151.
15. Connolly S.J., Ezekowitz M.D., Yusuf S. et al. Newly Identified Events in the RE-LY Trial. N Engl J Med 2010; 363(19): 1875 - 1876.
16. Healey J.S., Eikelboom J., Wallentin L. et al. Effect of age and renal function on the risk of stroke and major bleeding with dabigatran compared to warfarin: an analysis from the RE-LY study. JACC 2010; 55: A4. E37.
17. Oldgren J., Alings M., Darius H. et al. Dabigatran versus warfarin in atrial fibrillation patients with low, moderate and high CHADS2 score: a RE-LY subgroup analysis. JACC 2010; 55: A1. E2.
18. Diener H.-C., Connolly S.J., Ezekowitz M.D. et al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurology 2010; 9(12): 1157 - 1163.
19. Lane D.A., Lip G.Y.H. Dabigatran in atrial fibrillation: balancing secondary stroke prevention against bleeding risk. Lancet Neurology 2010; 9(12): 1140 - 1142.
20. Ezekowitz M.D., Wallentin L., Connolly S.J. et al. Comparison between the effects of dabigatran versus warfarin in Vitamin K antagonist naive and experienced patients with atrial fibrillation in the the RE-LY Trial. Circulation 2010; 122(22): 2246 - 2253.
21. Wallentin L., Yusuf S., Ezekowitz M.D. et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010; 376(9745): 975 - 983.
22. Nagarakanti R., Ezekowitz M.D., Oldgren J. at al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation 2011; 123(2):131-6.
23. Roskel N.S., Lip G.Y.H., Noak H. et al. Treatments for stroke prevention in atrial fibrillation: A network meta-analyses and indirect comparisons versus dabigatran etexilate. Thromb Haemost 2010; 104(6): 1106 - 1115.
24. Ahrens I., Lip G.Y., Peter K. What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation? Thromb Haemost 2011;105(4)..
25. Lopes R.D., Alexander J.H., Al-Khatib S.M. et al.; ARISTOTLE Investigators. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J 2010;159(3):331-9.